Clinical Trial Update: Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study evaluating a combination of liposomal doxorubicin, melphalan, and bortezomib in patients with relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Melphalan (Melphalan)
• Velcade (bortezomib)

Snippet

Sponsor: Herbert Irving Comprehensive Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1, Phase 2 | Status: UNKNOWN